Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors

Anti-Cancer Drugs

Volumn 15, Issue 5, 2004, Pages 469-471

  Abad, Albert ^a   Massutí, Bartomeu ^b   Gallego, Javier ^c   Yuste, Ana L ^b   Manzano, José Luis ^a   Carrato, Alfredo ^c   Antón, Antonio ^d   Marfa, Xavier ^e   Diaz Rubio, Eduardo ^f  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^e Sanofi Syntelabo   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

5 fluorouracil; Chemotherapy; Colorectal cancer; Irinotecan; Oxaliplatin

Indexed keywords

FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; FEMALE; HUMAN; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 2942574540     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000127146.50172.8a     Document Type: Article

References (11)

1. Giachetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan P, et al. Phase 111 multicentre randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-147.
2. De Gramont A, Figer A, Seymor M, Homerin M, Hmissi A, Cassidy J, et al. A randomized trial of leucovorin and 5-fluorouracil with or without oxaliplatin in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
3. Douillart JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:9209.
4. Saltz LB, Xoc JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Eng J Med 2000; 343:905-914.
5. Souglakos J, Mavroudis D, Kakolyris S, Kourousis Ch, Vardakis N, Androulakis N, et al. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol 2002; 20:2651-2657.
6. Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002; 20:4006-4014.
7. Abad A, Navarro M, Sastre J, Cervantes A, Antón A, Marcuello E, et al. Biweekly oxaliplatin (OXA) plus weekly 48 h continuous infusion (CI) 5FU in first line treatment of advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 2000; 19:300a.
8. Aranda E, Massuti B, Rivera F, Marcuello E, Abad A, Carrato A, et al. A phase II study of irinotecan (CPT-11) in combination with high dose 5-FU as a continuous infusion (ci) in patients (pts) with advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 2002; 21:116b.
9. Bismuth h, Adam R, Levi F, Farabos Ch, Waechter F, Castaing D, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224:509-522.
10. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kutslinger F, et al. Long term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663-669.
11. Adam R, Avisar E, Ariche A, Giacchetti S, Azoulay D, Castaing D, et al. Five year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8:347-353.